HK1123992A1 - Methods for reducing cd36 expression - Google Patents

Methods for reducing cd36 expression

Info

Publication number
HK1123992A1
HK1123992A1 HK09103915.7A HK09103915A HK1123992A1 HK 1123992 A1 HK1123992 A1 HK 1123992A1 HK 09103915 A HK09103915 A HK 09103915A HK 1123992 A1 HK1123992 A1 HK 1123992A1
Authority
HK
Hong Kong
Prior art keywords
expression
reducing
methods
Prior art date
Application number
HK09103915.7A
Other languages
English (en)
Inventor
Hazel H Szeto
Shaoyi Liu
Sunghee Cho
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Publication of HK1123992A1 publication Critical patent/HK1123992A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
HK09103915.7A 2005-09-16 2009-04-28 Methods for reducing cd36 expression HK1123992A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71817005P 2005-09-16 2005-09-16
PCT/US2006/036291 WO2007035640A2 (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression

Publications (1)

Publication Number Publication Date
HK1123992A1 true HK1123992A1 (en) 2009-07-03

Family

ID=37889419

Family Applications (4)

Application Number Title Priority Date Filing Date
HK09103915.7A HK1123992A1 (en) 2005-09-16 2009-04-28 Methods for reducing cd36 expression
HK13100442.9A HK1173367A1 (zh) 2005-09-16 2009-04-28 用於減少 表達的方法
HK15107494.9A HK1206971A1 (zh) 2005-09-16 2015-08-04 用於减少 表達的方法
HK16100693.2A HK1212718A1 (zh) 2005-09-16 2016-01-21 用於減少 表達的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK13100442.9A HK1173367A1 (zh) 2005-09-16 2009-04-28 用於減少 表達的方法
HK15107494.9A HK1206971A1 (zh) 2005-09-16 2015-08-04 用於减少 表達的方法
HK16100693.2A HK1212718A1 (zh) 2005-09-16 2016-01-21 用於減少 表達的方法

Country Status (10)

Country Link
US (9) US7541340B2 (zh)
EP (5) EP3725324A1 (zh)
JP (6) JP5416971B2 (zh)
KR (9) KR20150013353A (zh)
CN (6) CN104788540B (zh)
AU (1) AU2006292352B2 (zh)
CA (8) CA2947343C (zh)
DK (1) DK1931369T3 (zh)
HK (4) HK1123992A1 (zh)
WO (1) WO2007035640A2 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2656854T3 (en) 2003-02-04 2015-07-06 Cornell Res Foundation Inc Applications of an aromatic-cationic peptide
DK1625149T3 (en) 2003-05-01 2016-05-30 Cornell Res Foundation Inc METHOD AND carrying complexes for delivery of molecules to cells
CA2971928C (en) * 2004-01-23 2019-01-08 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US7687243B1 (en) * 2005-06-06 2010-03-30 Crook Tonia M Automated method for detecting apoptosis in cells
CA2947343C (en) 2005-09-16 2019-04-30 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
CN101939019B (zh) * 2008-02-07 2014-07-16 康奈尔大学 用于预防或治疗胰岛素抵抗性的方法
EP2262520B1 (en) * 2008-02-26 2017-05-03 Cornell University Compositions for prevention and treatment of renal injury
CN103933542A (zh) * 2009-03-20 2014-07-23 通用医疗公司以马萨诸塞州通用医疗公司名义经营 预防和治疗烧伤损伤和继发性并发症的方法
US20110039766A1 (en) * 2009-08-12 2011-02-17 Szeto Hazel H Methods for preventing or treating metabolic syndrome
EP3338788A1 (en) 2009-08-24 2018-06-27 Stealth Peptides International, Inc. Methods and copositions for preventing or treating opthalmic conditions
JP2013506696A (ja) * 2009-10-05 2013-02-28 コーネル ユニヴァーシティー 心不全の予防又は処置の方法
JP2013516425A (ja) * 2009-12-31 2013-05-13 ステルス ペプチドズ インターナショナル インコーポレイテッド 血管閉塞傷害の予防または治療方法
EP3443977A1 (en) * 2009-12-31 2019-02-20 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
CN103037901B (zh) * 2010-06-01 2018-04-27 康奈尔大学 抑制cd36以控制肥胖和胰岛素敏感性
CN107569675A (zh) * 2010-07-09 2018-01-12 康德生物医疗技术公司 预防或治疗缺血/再灌注损伤之后无复流的方法
EP3078384A1 (en) * 2012-02-22 2016-10-12 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CA2869080C (en) * 2012-03-30 2020-09-01 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
EP2879689A4 (en) * 2012-08-02 2015-12-16 Stealth Peptides Int Inc METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS
PL2936151T3 (pl) * 2012-12-18 2018-11-30 Biocrine Ab Sposoby leczenia i/lub ograniczania rozwoju cukrzycy
EP3586864A1 (en) * 2013-05-14 2020-01-01 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricle remodeling
CA2916492A1 (en) * 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
AU2014324580B2 (en) * 2013-09-30 2020-02-27 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
WO2015089316A1 (en) * 2013-12-12 2015-06-18 Cornell University Methods for preventing and treating oral cancers
WO2015095077A1 (en) * 2013-12-16 2015-06-25 Cornell University Methods and compositions for treating and preventing cognitive dysfunction
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
JP7103787B2 (ja) 2017-12-27 2022-07-20 太陽誘電株式会社 コイル部品及び電子機器
US11392555B2 (en) 2019-05-15 2022-07-19 Pure Storage, Inc. Cloud-based file services
WO2021021452A1 (en) * 2019-07-26 2021-02-04 The Board Of Trustees Of The Leland Stanford Junior University 1,8-cineol coated implants

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ATE136905T1 (de) * 1988-06-30 1996-05-15 Astra Ab Dermorphin-analoge, deren herstellungsverfahren, pharmazeutische zusammensetzungen und methode zur therapeutischen behandlung unter verwendung der analoge
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5747641A (en) * 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
EP0747092B1 (en) * 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
FR2756284B1 (fr) 1996-11-26 2000-04-28 Adir Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6268398B1 (en) * 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
DE60042338D1 (de) * 1999-10-04 2009-07-16 Univ New Jersey Med TAR RNA bindende Peptide
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
DE60143945D1 (de) 2000-07-18 2011-03-10 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu-opioid rezeptors
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
JP4881535B2 (ja) * 2000-10-20 2012-02-22 ハンブルガー・シュティフトゥング・ツーア・フェルデルング・フォン・ヴィッセンシャフト・ウント・クルトゥーア 酸化タンパク質、およびその生物活性、該活性メカニズム、該タンパク質の使用およびその阻害から誘導される治療的かつ診断的方法
DE10051983A1 (de) 2000-10-20 2002-06-13 Beate Kehrel Inhibierung der pathogenen Wirkung oxidierter Proteine
NZ529308A (en) 2001-04-05 2005-03-24 Collagenex Pharm Inc Tetracycline compounds comprising a tetracycline and a controlled release agent to provide delivery at a dose below that required for antibiotic activity
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
AU2002360460A1 (en) * 2001-12-03 2003-06-17 Nuvelo, Inc. Methods and materials relating to novel polypeptides and polynucleotides
JP4346870B2 (ja) * 2002-07-05 2009-10-21 キッコーマン株式会社 血糖値上昇抑制用組成物
AU2003259340A1 (en) * 2002-08-23 2004-03-11 Gestion Univalor Societe En Commandite Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia
DK2656854T3 (en) * 2003-02-04 2015-07-06 Cornell Res Foundation Inc Applications of an aromatic-cationic peptide
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
DK1625149T3 (en) 2003-05-01 2016-05-30 Cornell Res Foundation Inc METHOD AND carrying complexes for delivery of molecules to cells
MXPA05011830A (es) 2003-05-09 2006-01-26 Novo Nordisk As Peptidos para uso en el tratamiento de la obesidad.
US20050012597A1 (en) 2003-07-02 2005-01-20 Anderson Peter Traneus Wireless electromagnetic tracking system using a nonlinear passive transponder
US7232824B2 (en) * 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
EP1529533A1 (en) * 2003-11-06 2005-05-11 Sahltech I Göteborg AB Use of GH secretagogues in hypoxic-ischemic brain injury
CA2549482A1 (en) 2003-12-12 2005-06-23 Japan Science And Technology Agency Megsin/rage/inos overexpressing renaldisease model animals and methods for evaluating compounds using the model animals
CA2971928C (en) 2004-01-23 2019-01-08 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US8157123B2 (en) * 2005-02-23 2012-04-17 The Glad Products Company Container
CA2947343C (en) * 2005-09-16 2019-04-30 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
US20070259377A1 (en) 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
CN101939019B (zh) * 2008-02-07 2014-07-16 康奈尔大学 用于预防或治疗胰岛素抵抗性的方法
EP2262520B1 (en) 2008-02-26 2017-05-03 Cornell University Compositions for prevention and treatment of renal injury
JP2012181082A (ja) * 2011-03-01 2012-09-20 Tokyo Electric Power Co Inc:The 仕切弁の分解点検補助装置およびその案内治具、並びに仕切弁の分解点検方法
CN202756379U (zh) 2012-07-13 2013-02-27 滨中元川金属制品（昆山）有限公司 一种自攻牙螺丝

Also Published As

Publication number Publication date
EP1931369A2 (en) 2008-06-18
HK1173367A1 (zh) 2013-05-16
CA2947343A1 (en) 2007-03-29
EP1931369B1 (en) 2016-08-17
CN103784937B (zh) 2017-04-26
HK1212718A1 (zh) 2016-06-17
EP3260127B1 (en) 2019-05-01
KR20140106761A (ko) 2014-09-03
US20070129306A1 (en) 2007-06-07
DK1931369T3 (en) 2016-12-12
US20100317571A1 (en) 2010-12-16
KR20140042940A (ko) 2014-04-07
KR20160057372A (ko) 2016-05-23
CN107412723A (zh) 2017-12-01
EP1931369A4 (en) 2012-05-02
CA2947328C (en) 2019-03-05
KR20190084025A (ko) 2019-07-15
CN104324360A (zh) 2015-02-04
US7811987B2 (en) 2010-10-12
US20140256620A1 (en) 2014-09-11
JP5809649B2 (ja) 2015-11-11
JP2012233005A (ja) 2012-11-29
CN104788540A (zh) 2015-07-22
KR101621493B1 (ko) 2016-05-16
CA2947341C (en) 2019-03-05
US20090264369A1 (en) 2009-10-22
WO2007035640A3 (en) 2007-11-22
CA2947330C (en) 2018-06-05
CA2947335A1 (en) 2007-03-29
JP2015164953A (ja) 2015-09-17
EP3260127A1 (en) 2017-12-27
CN102552874A (zh) 2012-07-11
KR101999756B1 (ko) 2019-07-12
US7541340B2 (en) 2009-06-02
CN101296704A (zh) 2008-10-29
CA2947330A1 (en) 2007-03-29
CN104788540B (zh) 2019-10-18
CA2622911A1 (en) 2007-03-29
JP2009509941A (ja) 2009-03-12
CN103784937A (zh) 2014-05-14
KR20150013353A (ko) 2015-02-04
US20140249075A1 (en) 2014-09-04
US8603971B2 (en) 2013-12-10
US20210047369A1 (en) 2021-02-18
CA2947340A1 (en) 2007-03-29
CA2947341A1 (en) 2007-03-29
EP3549594A1 (en) 2019-10-09
US9150614B2 (en) 2015-10-06
JP2017066161A (ja) 2017-04-06
US20190248833A1 (en) 2019-08-15
KR20080050497A (ko) 2008-06-05
KR20150013354A (ko) 2015-02-04
JP5416971B2 (ja) 2014-02-12
WO2007035640A2 (en) 2007-03-29
CA2947340C (en) 2019-05-07
CN102552874B (zh) 2015-04-22
JP6157539B2 (ja) 2017-07-05
KR101426070B1 (ko) 2014-08-01
EP3095454A1 (en) 2016-11-23
EP3725324A1 (en) 2020-10-21
CA2622911C (en) 2016-12-06
US20170305967A1 (en) 2017-10-26
US20230212220A1 (en) 2023-07-06
CA2947343C (en) 2019-04-30
CA2947328A1 (en) 2007-03-29
HK1206971A1 (zh) 2016-01-22
JP2013075915A (ja) 2013-04-25
JP6385476B2 (ja) 2018-09-05
US11447523B2 (en) 2022-09-20
KR20170105470A (ko) 2017-09-19
CN101296704B (zh) 2012-09-05
JP2015205931A (ja) 2015-11-19
JP5805596B2 (ja) 2015-11-04
CA2947333A1 (en) 2007-03-29
AU2006292352B2 (en) 2012-02-09
KR20160056863A (ko) 2016-05-20
AU2006292352A1 (en) 2007-03-29
JP6175107B2 (ja) 2017-08-02

Similar Documents

Publication Publication Date Title
HK1212718A1 (zh) 用於減少 表達的方法
EP1864785A4 (en) SETEROLITHOGRAPHIEVERFAHREN
GB0504774D0 (en) Method
GB0503836D0 (en) Method
GB0509433D0 (en) Method
GB0504096D0 (en) Method
GB0507123D0 (en) Method
GB0504184D0 (en) Method
GB0510536D0 (en) Method
GB0525957D0 (en) Methods
GB0508420D0 (en) Method
GB0505756D0 (en) Method
GB0502046D0 (en) Method
GB0509305D0 (en) Method
GB0509437D0 (en) Method
GB0504182D0 (en) Method
GB0715741D0 (en) Methods
GB0518425D0 (en) Methods
GB0516204D0 (en) Methods
GB0526212D0 (en) Methods
GB0509956D0 (en) Method
GB0506670D0 (en) Method
GB0502360D0 (en) Method
GB0514661D0 (en) Methods
GB0507289D0 (en) Methods